← Back to Investors

Celgene (now Bristol Myers Squibb)

Celgene was a major biopharmaceutical company with active corporate venture investments. Acquired by Bristol Myers Squibb in 2019 for $74B. Historical investments in genomics, cell therapy, and oncology continue under BMS umbrella.

Location
Summit, USA (historical)
Founded
1986
AUM
N/A (acquired)
Investment Range
$10M - $100M (historical)
Focus
cvc
Fund Stages
seed, series-a, series-b, series-c, growth

Investment Thesis

Celgene's venture arm made strategic investments in companies developing innovative therapies, particularly in oncology, immunology, and inflammation. Post-acquisition, Bristol Myers Squibb continues strategic investing through its business development organization.

Team

Historical Partners / Managing Directors (Health & Bio Focus)

  • Mark Alles - Former CEO
  • Scott Smith - Former EVP

Bristol Myers Squibb Leadership

  • Chris Boerner, PhD - CEO, BMS

Focus Areas

  • Oncology
  • Immunology
  • Cell Therapy
  • Gene Therapy
  • Inflammation
  • Hematology

Notable Exits

  • Juno Therapeutics - Acquired (2018, by Celgene for $9B)
  • Impact Biomedicines - Acquired (2018, by Celgene for up to $7B)
  • Multiple strategic partnerships converted to acquisitions

Sources